Metabolic and appetite hormone responses of hyperinsulinemic normoglycemic males to meals with varied macronutrient compositions

Aims: The aim of this study was to investigate the appetite hormones and metabolic responses of hyperinsulinemic subjects to high-protein (HP) meals as compared to high-carbohydrate (HC) and high-fat (HF) meals. Design: Fifteen hyperinsulinemic normoglycemic men received, on 3 separate occasions, HP, HC, or HF meals in a randomized crossover design. Blood samples were collected before and after the ingestion of each meal. Postprandially, acylated ghrelin, PYY 3-36, insulin, glucose, and triglycerides were measured. Results: While the HC meal induced an acutely greater postprandial ghrelin decrease below baseline, the HP meal maintained this decline significantly more than the HF meal at 240 min. Postprandial PYY3-36 responses did not significantly vary with time and meal composition. Postprandial insulin and glucose peaks were significantly lower following the HP and HF meals in comparison to the HC meal, whereas triglyceride responses were significantly higher following the HF meal. Significant correlations, negative between acylated ghrelin and insulin and positive between PYY3-36 and insulin, were observed. Conclusions: In hyperinsulinemic normoglycemic men, HP meals ensure a longer-lasting suppression of circulating ghrelin levels and result in more favorable metabolic responses, characterized by a lower surge of postprandial insulin and glucose and a reduced postprandial triglyceride response, as compared to both HC and HF meals. Copyright © 2010 S. Karger AG, Basel.

ADRIAN TE, 1985, GASTROENTEROLOGY, V89, P1070; Al Awar R, 2005, CLIN SCI, V109, P405, DOI 10.1042-CS20050072; Anthony K, 2006, DIABETES, V55, P2986, DOI 10.2337-db06-0376; Baba NH, 1999, INT J OBESITY, V23, P1202, DOI 10.1038-sj.ijo.0801064; Bacha F, 2005, J CLIN ENDOCR METAB, V90, P2725, DOI 10.1210-jc.2004-1582; Barber TM, 2008, EUR J ENDOCRINOL, V158, P511, DOI 10.1530-EJE-07-0683; Batterham RL, 2003, NEW ENGL J MED, V349, P941, DOI 10.1056-NEJMoa030204; Batterham RL, 2006, CELL METAB, V4, P223, DOI 10.1016-j.cmet.2006.08.001; Boey D, 2006, NEUROPEPTIDES, V40, P317, DOI 10.1016-j.npep.2006.08.002; Boey D, 2006, DIABETOLOGIA, V49, P1360, DOI 10.1007-s00125-006-0237-0; BOIVIN M, 1990, GASTROENTEROLOGY, V99, P1763; Brand-Miller JC, 2000, METABOLISM, V49, P1, DOI 10.1016-S0026-0495(00)90488-8; Ceriello A, 1998, DIABETES CARE, V21, P1529, DOI 10.2337-diacare.21.9.1529; Chan JL, 2006, DIABETOLOGIA, V49, P169, DOI 10.1007-s00125-005-0041-2; Chandalia M, 2000, NEW ENGL J MED, V342, P1392, DOI 10.1056-NEJM200005113421903; Cummings DE, 2003, ARCH SURG-CHICAGO, V138, P389, DOI 10.1001-archsurg.138.4.389; De Schepper H, 2004, NEUROGASTROENT MOTIL, V16, P567, DOI 10.1111-j1365-2982.2004.00533.x; Eisenstein J, 2002, NUTR REV, V60, P189, DOI 10.1301-00296640260184264; El Khoury DTD, 2006, ANN NUTR METAB, V50, P260, DOI 10.1159-000091684; Erdmann J, 2009, REGUL PEPTIDES, V152, P1, DOI 10.1016-j.regpep.2008.10.008; Essah PA, 2007, J CLIN ENDOCR METAB, V92, P4052, DOI 10.1210-jc.2006-2273; Gaenzer H, 2001, CARDIOVASC RES, V52, P509, DOI 10.1016-S0008-6363(01)00427-8; GRANDT D, 1994, REGUL PEPTIDES, V51, P151, DOI 10.1016-0167-0115(94)90204-6; Greenman Y, 2004, CLIN ENDOCRINOL, V60, P382, DOI 10.1111-j.1365-2265.2004.01993.x; Hwalla N, 2005, NUTR RES, V25, P535, DOI 10.1016-j.nutres.2005.05.002; Keogh JB, 2007, BRIT J NUTR, V97, P405, DOI 10.1017-S0007114507252687; Layman DK, 2008, AM J CLIN NUTR, V87, p1571S; Leonetti F, 2004, REGUL PEPTIDES, V122, P179, DOI 10.1016-j.regpep.2004.06.014; Liu JK, 2006, J HYPERTENS, V24, P1391, DOI 10.1097-01.hjh.0000234120.71142.6c; Marzullo P, 2004, J CLIN ENDOCR METAB, V89, P936, DOI 10.1210-jc.2003-031328; McLaughlin T, 2004, J CLIN ENDOCR METAB, V89, P1630, DOI 10.1210-jc.2003-031572; Monteleone P, 2003, J CLIN ENDOCR METAB, V88, P5510, DOI 10.1210-jc.2003-030797; Moran LJ, 2004, J CLIN ENDOCR METAB, V89, P3337, DOI 10.1210-jc.2003-031583; Nilsson M, 2004, AM J CLIN NUTR, V80, P1246; Poykko SM, 2003, DIABETES, V52, P2546, DOI 10.2337-diabetes.52.10.2546; Purnell JQ, 1997, CURR OPIN LIPIDOL, V8, P17, DOI 10.1097-00041433-199702000-00005; Reaven GM, 1997, CURR OPIN LIPIDOL, V8, P23, DOI 10.1097-00041433-199702000-00006; Schulze MB, 2004, DIABETES CARE, V27, P613, DOI 10.2337-diacare.27.2.613; Shishehbor F, 1999, BRIT J NUTR, V81, P25; STONE NJ, 1994, MED CLIN N AM, V78, P117; Stubbs RJ, 1998, P NUTR SOC, V57, P341, DOI 10.1079-PNS19980052; Tome D, 2004, BRIT J NUTR, V92, pS27, DOI 10.1079-BJN20041138; Torbay N, 2002, NUTR RES, V22, P587, DOI 10.1016-S0271-5317(02)00359-7; Torekov SS, 2005, DIABETES, V54, P2261, DOI 10.2337-diabetes.54.7.2261; Viardot A, 2008, INT J OBESITY, V32, P943, DOI 10.1038-ijo.2008.24; Weigle DS, 2003, J CLIN ENDOCR METAB, V88, P1577, DOI 10.1210-jc.2002-021262; Wren AM, 2001, J CLIN ENDOCR METAB, V86, P5992, DOI 10.1210-jc.86.12.5992; Zwirska-Korczala K, 2007, J PHYSIOL PHARMACOL, V58, P13

3

4

4